Cat. No.: DAB-0011962
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IP, IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the sequence of human DHCR24/Seladin-1. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | DHCR24 |
| UniProt No. | Q15392 |
| Gene ID | 1718 |
| Gene Description | DHCR24/Seladin-1 was identified as a molecular basis for desmosterolosis. It encodes for 24-dehydrocholesterol reductase. This enzyme reduces desmosterol in cholesterol biosynthesis. Recessive mutations in this gene in desmosterolosis patients lead to a defective enzyme resulting in increased levels of desmosterol. DHCR24/Seladin-1 is induced upon oxidative stress and was found to mediate Ras-induced senescence resulting from increased reactive oxygen species. Studies further indicate that the level of DHCR24/Seladin-1 is induced in the acute response and reduced in the chronic response to oxidative stress in a cholesterol dependent manner. Moreover, overexpression of DHCR24/Seladin-1 bearing two mutations that abolish its reductase acitivity causes the cells to lose protection from oxidative stress. These findings thus link the reductase activity of DHCR24/Seladin-1 to its protective role in oxidative stress. This enzyme has also been demonstrated to be a hydrogen peroxide scavenger. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
